The 20 Best Large-Cell Immunoblastic Lymphoma Doctors Near Me in Towson, MD

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Transplant. Dr. Swinnen is board certified in American Board Of Internal Medicine.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration. Dr. Ambinder is board certified in American Board Of Internal Medicine.

Richard Schraeder is a Hematologist and an Oncologist practicing medicine in Towson, Maryland. Dr. Schraeder is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 61 other conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Retroperitoneal Liposarcoma. Dr. Schraeder is currently accepting new patients.

Mei Tang is a Hematologist practicing medicine in Towson, Maryland. Dr. Tang is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. She is also highly rated in 43 other conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Myelodysplastic Syndrome (MDS), and Large-Cell Immunoblastic Lymphoma.

Paul Celano is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Celano is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Testicular Yolk Sac Tumor, Ovarian Carcinosarcoma, and Virilizing Ovarian Tumor.

Ravin Garg is a Hematologist Oncology specialist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Garg is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 58 other conditions, according to our data. His clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, and Thrombotic Thrombocytopenic Purpura. Dr. Garg is board certified in American Board Of Internal Medicine.

Maitri Kalra is a Hematologist Oncology specialist and an Oncologist practicing medicine in Lutherville, Maryland. She has been practicing medicine for over 17 years. Dr. Kalra is rated as an Experienced provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. She is also highly rated in 4 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Kalra is board certified in American Board Of Internal Medicine.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Advanced provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Advanced provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration. Dr. Fuchs is board certified in American Board Of Internal Medicine.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Non-Hodgkin Lymphoma, and Myelodysplastic Syndrome (MDS). Dr. Jones is board certified in American Board Of Internal Medicine.

William Houck is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Houck is rated as an Advanced provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 73 other conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Richter Syndrome. Dr. Houck is board certified in American Board Of Internal Medicine.

Syed Nasir is an Oncologist practicing medicine in Towson, Maryland. Dr. Nasir is rated as an Advanced provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 85 other conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast. Dr. Nasir is currently accepting new patients.

Gang Chen is a Hematologist practicing medicine in Towson, Maryland. Dr. Chen is rated as an Experienced provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Colorectal Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast.

Charles Padgett is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Padgett is rated as an Advanced provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and EGFR Positive Lung Cancer.

Mayer Gorbaty is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Gorbaty is rated as an Advanced provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 35 other conditions, according to our data. His clinical expertise encompasses Monoclonal Gammopathy of Undetermined Significance (MGUS), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, and Multiple Myeloma.

John Downs is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Downs is rated as an Advanced provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Large-Cell Immunoblastic Lymphoma, Lung Cancer, and Pleuropulmonary Blastoma.

David Riseberg is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Riseberg is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer.

Sandy Kotiah is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Kotiah is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. She is also highly rated in 42 other conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Paget Disease of the Breast, Anemia, Lynch Syndrome, and Bone Marrow Aspiration.

Dr. Civelek is a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. He serves as the director of the Nuclear Medicine Residency Program. Dr. Civelek earned his medical degree at Istanbul University, Istanbul School of Medicine, and completed his residency at Hacettepe University Medical Center, Ankara. He received a scholarship from the International Atomic Energy Agency when he completed his nuclear medicine residency and fellowship at Johns Hopkins in the Division of Nuclear Medicine. After his period as a postdoctoral fellow, he joined Johns Hopkins Medicine as full-time faculty until 2003. In his early years at Johns Hopkins, Dr. Civelek assisted the clinical and research programs. He later served as director of nuclear cardiology and clinical director, the director of Nuclear Medicine Residency Program, as well as medical director of the Nuclear Medicine Technologist Program. Prior to his return to Johns Hopkins, Dr. Civelek was a professor and director of nuclear medicine and PET at the University of Louisville and a professor and director of nuclear medicine at the Saint Louis University Hospital. Dr. Civelek spent two years in the body MRI and MRI-PET section, Department of Radiology and Imaging Sciences, at National Institutes of Health Clinical Center before serving as the deputy chief in their nuclear medicine section. He is a fellow of the American College of Nuclear Medicine and The American College of Angiology, and is a fellow and founding member of the American Society of Nuclear Cardiology. Dr. Civelek has trained numerous American and international physicians in nuclear medicine, including nuclear cardiology and nuclear oncology. He has a worldwide reputation in nuclear medicine and lectures at medical centers in the U.S. and internationally on nuclear medicine, including nuclear cardiology and nuclear oncology/PET-CT and PET-MRI. Dr. Civelek is committed to the continued progress of nuclear medicine, cardiology and oncology and the development of new tumor-targeting radiopharmaceuticals for imaging and therapy. He supports high quality clinical trials and patient care and safety. To date, Dr. Civelek has published more than 210 peer-reviewed manuscripts and abstracts, and he has participated in and fostered many nuclear oncology research projects. He has served on the editorial boards of several journals. He is a reviewer for multiple scientific journals, including the Journal of Nuclear Medicine, American Journal of Radiology, and Journal of Urology. Dr. Civelek is rated as an Experienced provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Prostate Cancer, Lung Cancer, and Familial Prostate Cancer. Dr. Civelek is board certified in American Board Of Nuclear Medicine.

I am a physician-scientist in the Division of Hematological Malignancies and stem cell transplantation at the Sidney Kimmel Comprehensive Cancer Center, where I specialize in the treatment of lymphomas. My primary research focuses on developing new biologic therapies for the treatment of T-cell lymphomas and T-cell leukemias. Dr. Paul is rated as an Experienced provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. His clinical expertise encompasses Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, and T-Cell Lymphoma. Dr. Paul is board certified in American Board Of Internal Medicine.